Bionano Genomics, Inc. Warrant
BNGOW
BNGOW was delisted on the 17th of August, 2023.
4 hedge funds and large institutions have $216K invested in Bionano Genomics, Inc. Warrant in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0% more funds holding
Funds holding: 4 → 4 (0)
67% less capital invested
Capital invested by funds: $658K → $216K (-$442K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$403K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Trading
New York
|
-$196K |
BNGOW Hedge Fund Activity: Q4 2018 in Review
4 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics, Inc. Warrant (BNGOW) for Q4 2018, worth a combined $216K — down 67% from $658K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BNGOW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $403K. The largest seller was Walleye Trading, exiting entirely with an estimated $196K sold.
- 4 institutional investors held Bionano Genomics, Inc. Warrant (BNGOW) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $216K of Bionano Genomics, Inc. Warrant stock for Q4 2018, down 67% quarter-over-quarter.
- 2 funds opened new Bionano Genomics, Inc. Warrant positions in Q4 2018 and 1 closed out, a net change of +1 holder.
- The largest Bionano Genomics, Inc. Warrant buyer in Q4 2018 was Monashee Investment Management, an estimated $403K added.
- The largest Bionano Genomics, Inc. Warrant seller in Q4 2018 was Walleye Trading, an estimated $196K sold.
Based on aggregated 13F filings for Q4 2018.